AMIX
Autonomix MedicalAMIX
AMIX
About: Autonomix Medical Inc is a development-stage medical device development company focused on advancing technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
Employees: 11
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
5.8% less ownership
Funds ownership: 12.07% [Q4 2024] → 6.26% (-5.8%) [Q1 2025]
7% less funds holding
Funds holding: 14 [Q4 2024] → 13 (-1) [Q1 2025]
70% less capital invested
Capital invested by funds: $477K [Q4 2024] → $144K (-$332K) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
250%
upside
Avg. target
$5
250%
upside
High target
$5
250%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Anthony Vendetti | 250%upside $5 | Buy Initiated | 29 Apr 2025 |
Financial journalist opinion
Based on 3 articles about AMIX published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment
THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, elaborates on the Company's recently announced planned follow-on market expansion study phase (“PoC 2”) of its proof-of-concept trial.
Neutral
GlobeNewsWire
1 week ago
Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study
Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy THE WOODLANDS, TX, June 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the first patient has been enrolled and treated in the follow-on phase to its proof-of-concept human clinical trial (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. “We're executing on a bold vision to expand the reach of our technology beyond pancreatic cancer pain and into a broader range of high-need visceral cancer indications,” said Brad Hauser, CEO of Autonomix.
Neutral
GlobeNewsWire
2 weeks ago
Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology
Patent supports the Company's broader mission to advance minimally invasive, nerve-focused treatments across high-need indications
Neutral
GlobeNewsWire
1 month ago
Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain
Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix's strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received Ethics Committee authorization from the Ministry of Health of the Republic of Uzbekistan to open the clinical trial site for the follow-on phase to its proof-of-concept human clinical trial (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. The Company is on track to commence enrollment in June 2025.
Positive
Zacks Investment Research
1 month ago
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
Autonomix Medical, Inc. AMIX recently announced that it has been granted a key U.S. patent for its innovative catheter-based platform designed to sense and differentiate nerve signals in real-time. This technology represents a significant leap forward in the field of neuromodulation, with the potential to enhance treatment precision across a wide range of chronic conditions, including cancer and pain management.
Neutral
GlobeNewsWire
1 month ago
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology
Patent strengthens Autonomix's intellectual property position in the nerve-mapping and denervation space, supporting the Company's broader mission to advance minimally invasive, nerve-focused therapeutics
Neutral
GlobeNewsWire
1 month ago
Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event
Live webcast followed by an interactive Q&A session on Thursday, May 22 nd at 4:00 PM ET
Neutral
GlobeNewsWire
1 month ago
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market
Discussion in Virtual Investor CEO Connect focuses on Company's planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here
Neutral
GlobeNewsWire
2 months ago
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain
Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care
Neutral
GlobeNewsWire
2 months ago
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated
Charts implemented using Lightweight Charts™